Blueprint Medicines (BPMC) Scheduled to Post Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC) last announced its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) EPS for the quarter, beating the consensus estimate of ($2.04) by $0.22. The company had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm’s revenue for the quarter was up 85.5% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.65) earnings per share. On average, analysts expect Blueprint Medicines to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Blueprint Medicines Stock Performance

Shares of BPMC stock opened at $92.29 on Wednesday. The firm has a 50-day moving average of $90.36 and a 200-day moving average of $78.32. The company has a market cap of $5.65 billion, a P/E ratio of -11.04 and a beta of 0.63. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66. Blueprint Medicines has a one year low of $43.89 and a one year high of $101.00.

Wall Street Analysts Forecast Growth

BPMC has been the subject of several analyst reports. Wedbush reiterated an “outperform” rating and issued a $97.00 target price on shares of Blueprint Medicines in a report on Monday, February 5th. Citigroup increased their price target on shares of Blueprint Medicines from $54.00 to $65.00 and gave the company a “sell” rating in a research report on Friday, February 16th. JMP Securities restated a “market outperform” rating and set a $114.00 price target on shares of Blueprint Medicines in a research report on Wednesday, April 10th. Barclays increased their price target on shares of Blueprint Medicines from $58.00 to $70.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Blueprint Medicines in a research report on Monday, February 26th. Four analysts have rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $85.43.

Insiders Place Their Bets

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 25,000 shares of the stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the completion of the transaction, the director now owns 176,050 shares in the company, valued at $14,420,255.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Christopher K. Murray sold 621 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $93.65, for a total value of $58,156.65. Following the completion of the transaction, the insider now directly owns 36,374 shares in the company, valued at $3,406,425.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey W. Albers sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the completion of the transaction, the director now owns 176,050 shares of the company’s stock, valued at $14,420,255.50. The disclosure for this sale can be found here. Insiders sold 117,289 shares of company stock worth $10,361,913 over the last quarter. 3.88% of the stock is currently owned by company insiders.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.